China Widens MAH Scheme To Medtech As Consumables Face Price Cuts

China is quickly expanding its marketing authorization holder scheme from drugs to devices. It is also vowing to reduce medical costs by using more low-cost, domestic consumables, which will have a significant impact on companies.

EU Chamber of Commerce in China president Jorg Wukket speaks at March 7 press briefing in Beijing, China.
CHINA MANUFACTURING 2025 IS AIMED TO ENCOURAGE MADE IN CHINA MEDICAL PRODUCTS • Source: Medtech Insight

China's marketing authorization holder mechanism is now being expanded to the medtech sector, and from the original four mega cities to 21 provinces, including the major medtech-producing provinces, Jiangsu, Zhejiang and Shandong.

International device makers can also leverage the MAH mechanism, which is a method of contracting manufacturing to local companies, which will reduce costs.

More from Regulation

More from Policy & Regulation